Penetration of SCH-39304, a new antifungal triazole, into cerebrospinal fluid of primates

We characterized the cerebrospinal fluid (CSF) penetration and pharmacokinetics of SCH-39304 in adult rhesus monkeys receiving a single oral dose of SCH-39304 (2.0 mg/kg of body weight). The mean CSF-to-plasma area under the curve ratio was 0.63 (+/- 0.18, standard error of the mean); maximum concentrations were 1.34 micrograms/ml (+/- 0.18) in CSF and 1.96 micrograms/ml (+/- 0.43) in plasma. The mean plasma half-life was 45.7 h (+/- 11), and mean CSF half-life was 38.7 h (+/- 3.5). The mean levels of SCH-39304 at 24 h were 1.48 micrograms/ml (+/- 0.3) in plasma and 0.96 microgram/ml (+/- 0.12) in CSF. We conclude that SCH-39304 effectively penetrates into CSF and achieves concentrations considered active against many opportunistic yeasts and that these concentrations are sustained in CSF for greater than or equal to 24 h.

[1]  D. Loebenberg,et al.  Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits , 1989, Antimicrobial Agents and Chemotherapy.

[2]  J. Perfect,et al.  Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304 , 1989, Antimicrobial Agents and Chemotherapy.

[3]  T. Walsh,et al.  Infections due to Xylohypha bantiana (Cladosporium trichoides). , 1989, Reviews of infectious diseases.

[4]  J. Galgiani,et al.  In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy , 1989, Antimicrobial Agents and Chemotherapy.

[5]  T. Walsh,et al.  Pharmacokinetics and tissue penetration of fluconazole in rabbits , 1989, Antimicrobial Agents and Chemotherapy.

[6]  A. Sugar,et al.  Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. , 1988, The American journal of medicine.

[7]  A. Zuger,et al.  Maintenance amphotericin B for cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS). , 1988, Annals of internal medicine.

[8]  A. Catanzaro,et al.  Fluconazole Penetration into Cerebrospinal Fluid in Humans , 1988, Journal of clinical pharmacology.

[9]  F. Balis,et al.  Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. , 1988, The Journal of infectious diseases.

[10]  A. Zuger,et al.  Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. , 1986, Annals of internal medicine.

[11]  B. Polsky,et al.  Treatment of infections in patients with the acquired immunodeficiency syndrome. , 1985, Annals of internal medicine.

[12]  E. Gelmann,et al.  Cryptococcosis in the acquired immunodeficiency syndrome. , 1985, Annals of internal medicine.

[13]  J. Perfect,et al.  Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. , 1985, The Journal of antimicrobial chemotherapy.

[14]  G. Curt,et al.  Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone. , 1984, Cancer research.

[15]  D. Warnock,et al.  Clinical Pharmacokinetics of Systemic Antifungal Drugs , 1983, Clinical pharmacokinetics.

[16]  D. Alling,et al.  A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. , 1979, The New England journal of medicine.

[17]  A. Espinel-Ingroff,et al.  Therapeutic Failures with Miconazole , 1978, Antimicrobial Agents and Chemotherapy.

[18]  J. Galgiani,et al.  Treatment of fungal meningitis with miconazole. , 1977, Archives of internal medicine.

[19]  A. Ommaya,et al.  Chronic ventricular cerebrospinal fluid sampling, drug injections, and pressure monitoring using subcutaneous reservoirs in monkeys. , 1977, Neurosurgery.

[20]  A. Ommaya,et al.  Primate model for long-term study of intraventricularly or intrathecally administered drugs and intracranial pressure. , 1977, Science.